Narrative review compares long-acting growth hormone to daily recombinant human GH in pediatric GH deficiency

This narrative review examines the use of long-acting growth hormone formulations compared to daily recombinant human GH in the treatment of pediatric patients with GH deficiency. The scope of the article covers secondary outcomes including linear growth, safety profile, patient adherence, and dosing intervals. The authors do not report a specific sample size or follow-up duration for the synthesized evidence. The review notes that efficacy was shown in promoting linear growth, although specific effect sizes or absolute numbers were not reported in the source text. Regarding safety, the profile of long-acting formulations is described as comparable to daily recombinant human GH therapy. Specific adverse events, serious adverse events, discontinuations, and tolerability data were not reported in the source material. The review does not provide statistical measures such as p-values or confidence intervals for the pooled findings. Funding sources and potential conflicts of interest were not reported. The authors do not overstate the certainty of the findings given the observational nature of the synthesized data. Practice relevance is discussed without specific quantitative guidance on dosing or long-term outcomes.